An Australian partner of international law firm Jones Day has moved to the firm’s Singapore office to bolster its growing team of international arbitration specialists.
International law firm Jones Day has expanded its intellectual property team in Sydney, hiring experienced patent litigator Andrew Rankine from Ashurst as its second local partner.
The Full Federal Court has expedited an appeal filed Christmas Eve by Sanofi-Aventis of a ruling that denied its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
From a record-setting funder’s cut to the first call for ‘“proportionality”, last year saw a number of groundbreaking judgments approving class action settlements worth more than half a billion dollars. Here are the 10 biggest settlements of 2018, and the law firms and funders that negotiated them.
French pharmaceutical giant Sanofi has appealed a judge’s ruling denying its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
A barrister for two units of embattled wealth manager IOOF and three senior company executives facing claims by APRA have criticised the regulator for filing a broad concise statement and no statement of claim after a three-year investigation.
A judge has denied Sanofi’s bid to block Alphapharm from listing its insulin injector pen on the Pharmaceutical Benefit Scheme, saying Sanofi has not established a strong enough case of infringement to justify granting the injunction.
James Packer’s Crown Resorts has won a lawsuit against the NSW government for allegedly failing to protect sweeping views of the Sydney Harbour from its planned luxury casino in the Barangaroo area.
The Australian Securities and Investments Commission has promised it will stay away from the depositions of two former Rio Tinto executives in proceedings underway in the US, as it pursues a parallel case over allegedly misleading market statements the mining company made about the reserves of a $4 billion coal acquisition.
The Commonwealth has urged the court to strike out the “inconsistent” pleadings of pharmaceutical firms Otsuka and Bristol-Myers Squibb in a patent case over the antipsychotic drug Abilify, calling them a “scandal” which could bring disrepute to the administration of justice.